TAG:
cap
More IVD Consolidation as Danaher Acquires Iris
By Joseph Burns | From the Volume XIX No. – October 8, 2012 Issue
CEO SUMMARY: Danaher Corporation continues to fuel growth by continually acquiring in vitro diagnostics (IVD) companies. Its latest purchase is Iris International, which manufactures automated urine microscopy systems. Danaher also has $5 billion available that it could spend in the next …
Unprecedented Growth Rates for Molecular Testing
By Joseph Burns | From the Volume XIX No. – October 8, 2012 Issue
CEO SUMMARY: There will be an expanding role for innovative clinical labs as healthcare moves forward on its path toward personalized medicine. However, to capitalize on this opportunity, pathology groups and clinical labs will need to beef up their information systems. They will also nee…
Lab Specimen Transport Eliminates Need for Ice
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: Because of its unique design and reliability, a new product for transporting laboratory specimens and units of blood without the use of ice and dry ice is gaining favor with innovative laboratories across the country. Kaiser Permanente of the Mid-Atlantic States uses this ice…
Sonic Healthcare, Bio-Reference Report Financial Performance
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
IN RECENT WEEKS, two of the nation’s larger public laboratory companies issued their earnings reports. In both cases, revenue growth was strong, a distinct difference from the recent financial performance of their two largest lab public company competitors. It was on August 21, 2012, when …
Competitive Bidding: Once Again, It’s Back!
By Robert Michel | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: For the clinical lab industry, the concept of competitive bidding for Medicare Part B Clinical Lab Testing may be like the movie “Groundhog Day.” The hero, Bill Murray, kept reliving the same day over and over. So it seems to be with competitive bidding. In the latest rep…
Labs Have Questions about Prostate Biopsy Policy
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increas…
August 27, 2012 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
How big is the market for laboratory testing in China, with its 20,000 hospitals and population of 1.3 billion people? A new report estimates that the independent clinical laboratory industry in China currently generates about 2 billion Yuan Renminbi per year in revenue. This is equal to about US $31…
Damon Laboratories, Mitt Romney, and Politics
By R. Lewis Dark | From the Volume XIX No. 12 – August 27, 2012 Issue
IT IS SELDOM THAT THE CLINICAL LABORATORY INDUSTRY HITS THE RADAR SCREEN during a presidential election. So it is with some interest that I report to you that Mitt Romney recently touted the lessons he learned while serving on the board of Damon Clinical Laboratories, Inc., as useful…
Pathologists in China, U.S. Linked By Digital Pathology
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
Root Cause Analysis Used To Find Source of Errors
By Joseph Burns | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO SUMMARY: It is a reminder that today’s sophisticated laboratory test systems still have the potential to malfunction in unexpected ways. This spring, following installation and validation of a new chemistry instrument, one Canadian hospital laboratory quickly recognized that a serie…
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized